Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. due to allegations of misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to severe adverse events including patient deaths [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [2]. - The class period for the lawsuit is defined as between June 22, 2023, and June 24, 2025, during which investors acquired Sarepta securities [1]. Group 2: Impact of Adverse Events on Stock Price - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [3]. - Following the announcement on April 4, 2025, regarding regulatory scrutiny and the halting of recruitment in some clinical studies, Sarepta's stock fell more than 7% [4]. - A second patient death was reported on June 15, 2025, leading to a suspension of ELEVIDYS shipments and a further stock decline of over 42% [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure cases, causing an additional stock drop of more than 8% [6]. Group 3: Investor Actions - Investors who purchased Sarepta shares are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline of August 25, 2025, to discuss their rights and interests in the class action [7].